3 completed, 2 terminated. 3 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow rVA576: new trials by email Literature Review of rVA576 trials Research Report on rVA576
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Topical rVA576 for Treatment of Atopic Keratoconjunctivitis rVA576, Placebo - Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal | Phase 1 / Phase 2 | Terminated | AKARI Therapeutics | 12 | 2019-03-04 | 2025-04-10 |
| rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects rVA576 - Bullous Pemphigoid (BP) | Phase 2 | Completed | AKARI Therapeutics | 9 | 2018-09-25 | 2025-04-22 |
| Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576 rVA576, Standard of care (SOC) - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | Completed | AKARI Therapeutics | 9 | 2018-06-07 | 2025-04-09 |
| rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study rVA576 - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Terminated | AKARI Therapeutics | 15 | 2017-03-13 | 2025-04-10 |
| Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) Coversin - Paroxysmal Nocturnal Haemoglobinuria (PNH) | Phase 2 | Completed | AKARI Therapeutics | 1 | 2016-02-01 | 2023-07-12 |
Hemoglobinuria, Paroxysmal (3) · Conjunctivitis, Allergic (1) · Keratoconjunctivitis (1) · Pemphigoid, Bullous (1)
Netherlands (2) · Germany (1) · Kazakhstan (1) · Lithuania (1) · Poland (1) · Spain (1) · Sri Lanka (1) · United Kingdom (1)
Andrius Degulys, MBBS (1) · Petra Dr Muus (1) · Sajjad Ahmad (1) · Saskia Dr Langemeijer (1) · Wynne Weston Davies (1)